RNS Number: 3687X Diaceutics PLC 23 July 2024

Diaceutics PLC - Board Changes

Belfast and London, 23 July 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the following changes to its board.

Deborah Davis has today informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024.

Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.

Deborah Davis, Non-Executive Chair of Diaceutics commented: "With a mixture of pride and gratitude, I announce my decision to step down as Chair of Diaceutics. During my tenure, our collective efforts have scaled the Company and transformed its business model, delivering significant growth and positioning Diaceutics as a key commercialisation partner to pharma and biotech companies in their quest to find patients that benefit from their precision medicines. I extend my deepest gratitude to our board, executive team, employees, partners, and shareholders for their unwavering support. Under Peter's stewardship, I am confident the Company will continue to grow and succeed."

Ryan Keeling, Chief Executive Officer of Diaceutics commented:"I would like to thank Deborah for her tireless dedication and efforts in guiding Diaceutics through a crucial stage in our development and growth as a public company. We will miss her presence and wish her well for her current and future roles. I look forward to working closely with the board and continuing my close partnership with Peter in his new capacity as Chair."

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer Tel: +44 (0)28 9040 6500

Nick Roberts, Chief Financial Officer investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600

Ben Maddison Nick Harland Kate Hanshaw

Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almastrategic.com

Kinvara Verdon Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network *.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc/ms/seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END